Stoke Therapeutics, Inc.

NasdaqGS:STOK Stock Report

Mkt Cap: US$375.8m

Stoke Therapeutics Future Growth

How is Stoke Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


6.7%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

NasdaqGS:STOK - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202527-143-154N/A6
12/31/202413-141-144-1487
12/31/202310-122-115-10611
9/30/20229-100-30-26N/A
6/30/20226-96-20-18N/A
3/31/20223-94-16-14N/A
12/31/2021N/A-86-68-67N/A
9/30/2021N/A-76-63-62N/A
6/30/2021N/A-67-59-58N/A
3/31/2021N/A-58-52-52N/A
12/31/2020N/A-52-43-42N/A
9/30/2020N/A-48-43-41N/A
6/30/2020N/A-43-41-39N/A
3/31/2020N/A-38-37-35N/A
12/31/2019N/A-32-33-31N/A
9/30/2019N/A-26-26-24N/A
6/30/2019N/A-21-20-19N/A
3/31/2019N/A-16-17-16N/A
12/31/2018N/A-13-12-11N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: STOK is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: STOK is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: STOK is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: STOK's revenue (53.5% per year) is forecast to grow faster than the US market (6.9% per year).

High Growth Revenue: STOK's revenue (53.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: STOK is forecast to be unprofitable in 3 years.


Discover growth companies